Davis Polk advised Coloplast on its acquisition of Nine Continents Medical, an early stage company pioneering an implantable tibial nerve stimulation treatment for over-active bladder. The…
Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion,…
Davis Polk is advising Bristol Myers Squibb on its acquisition of Forbius. The transaction includes an upfront payment and future success-based milestone payments. The transaction is…
On July 17, 2020, Davis Polk secured a complete dismissal on behalf of its client, AstraZeneca, in an Anti-Terrorism Act (“ATA”) lawsuit asserted against several pharmaceutical and medical…
Davis Polk is advising J M Smith Corporation in connection with the sale of its technologies division, Smith Technologies, to private equity sponsor Francisco Partners, pursuant to a…
Davis Polk is advising Nutrisystem, Inc. on its $1.4 billion acquisition by Tivity Health, Inc. The transaction, which is expected to close in the first quarter of 2019, is subject to…
Davis Polk is advising Aetna in connection with an agreement with the U.S. Department of Justice that allows it to proceed with its proposed $77 billion acquisition by CVS Health and its…
Davis Polk is advising Aetna in connection with an agreement with the U.S. Department of Justice that allows it to proceed with its proposed $77 billion acquisition by CVS Health and its…
Davis Polk is advising China Biologic Products Holdings, Inc. (“CBPO”) in connection with its acquisition of 80% equity interest in Tianxinfu (Beijing) Medical Appliance Co., Ltd. from PW…
Davis Polk represents Aetna Inc. and its subsidiaries ActiveHealth Management, Inc. and Medicity, Inc. in a patent infringement suit brought by HealthTrio, LLC. HealthTrio filed the lawsuit…